David Carver Email

Business Development Director - Commercial . Selcia

Current Roles

Employees:
77
Revenue:
$15.5M
About
Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities. \n\n14C Custom Radiolabelling for pre-clinical ADME studies\n14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate) \nGMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance\nStable Labelling (13C, 2H, 15N) Internal Standards, Metabolites and Impurities\nStable Labelling 13C 2H 15N\nGLP Analysis Certification and Problem Solving including GLP NMR\n\nwww.selcia.com contact@selcia.com
Selcia Address
Fyfield Business and Research Park
Ongar, null
UK
Selcia Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.